Abstract
Breast cancer being the most malignant and lethal disease persistent among women globally. Immunotherapy as a new treatment modality has emerged in understanding the loopholes in the treatment of breast cancer which is mainly attributed to the potential of tumor cells to evade and survive the immune response by developing various strategies. Therefore, improved understanding of the immune evasion by cancer cells and the monoclonal antibodies against PD- and PD-L1 can help us in the diagnosis of this malignancy. Here in this article, I have highlighted that in addition to focusing on other strategies for breast cancer treatment, the involvement of immune system in breast cancer is vital for the understanding of this malignancy. Further, the complete involvement of immune system in the relapse or recurrence of the breast tumor and have also highlighted the role of vaccines, PD-1 and CTLA-4 with the recent advances in the field. Moreover, in addition to the application of immunotherapy as a sole therapy, combinations of immunotherapy with various strategies like targeting it with MEK inhibitors, Vaccines, chemotherapy and PARP inhibitor has shown to have significant benefits is also discussed in this article.
Subject
General Medicine,Immunology,Immunology and Allergy
Reference85 articles.
1. Cancer statistics, 2016;Siegel;CA: A Cancer Journal for Clinicians,2016
2. Clinical relevance of host immunity in breast cancer: from TILs to the clinic;Savas;Nature Reviews Clinical Oncology,2016
3. E.J. Lipson, P.M. Forde et al., Antagonists of PD-1 and PD-L1 in cancer treatment, in, Elsevier, pp. 587–600.
4. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape;Emens;European Journal of Cancer,2017
5. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade;Emens;Expert Review of Anticancer Therapy,2012
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献